Model-Informed Development of STAR-0310: Supporting Every-3-Month and Every-6-Month Dosing in Atopic Dermatitis

STAR-0310 - BioCryst Pharmaceuticals

rocatinlimab (AMG 451) - Kyowa Kirin

telazorlimab (ISB 830) - BioCryst Pharmaceuticals

https://eposters.aad.org/abstracts/75972

Raj Chovatiya MD; PhD; Stacey Luo; Zhiwei Zhang; Paul Jasper; Christopher Morabito; Ganesh Mugundu

Mar 12, 2026